Lattice Biologics Increases Size of Planned Debt-to-Equity Conversion

Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (“Lattice Biologics” or the “Company“) announced today that — subject to approval...

Lattice Biologics Launches AmnioVisc for Arthritic Joints

Lattice Biologics is pleased to announce the launch of AmnioVisc™, a minimally processed amniotic fluid supplement for the treatment of...